Population
Early breast cancer patients
Design
Cohort
Authors
Loading...
Supports ongoing cardiac surveillance in trastuzumab recipients; leaves open identification of risk and protective factors.
Trastuzumab-induced cardiotoxicity is a frequent but generally mild adverse event, highlighting the need for further studies to define risk and protective factors.
Farolfi et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: